Display options
Cite
Mantry PS, Mehta A, Madani B, et al. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol. 2017;8(5):799-807doi: 10.21037/jgo.2017.08.03.
Mantry, P. S., Mehta, A., Madani, B., Mejia, A., & Shahin, I. (2017). Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. Journal of gastrointestinal oncology, 8(5), 799-807. https://doi.org/10.21037/jgo.2017.08.03
Mantry, Parvez S, et al. "Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study." Journal of gastrointestinal oncology vol. 8,5 (2017): 799-807. doi: https://doi.org/10.21037/jgo.2017.08.03
Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol. 2017 Oct;8(5):799-807. doi: 10.21037/jgo.2017.08.03. PMID: 29184683; PMCID: PMC5674259.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Oncol. 2017 Oct;8(5):799-807. doi: 10.21037/jgo.2017.08.03.

Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study.

Journal of gastrointestinal oncology

Parvez S Mantry, Ashwini Mehta, Bahar Madani, Alejandro Mejia, Islam Shahin

Affiliations

  1. The Liver Institute and Interventional Radiology, Methodist Dallas Medical Center, Dallas, TX, USA.
  2. Department of Gastroenterology, Plaza Medical Center, Fort Worth, TX, USA.
  3. Scripps Clinic, La Jolla, CA, USA.

PMID: 29184683 PMCID: PMC5674259 DOI: 10.21037/jgo.2017.08.03

Abstract

BACKGROUND: Selective internal radiation therapy (SIRT) with yttrium-90 resin (Y-90 resin) microspheres has been used as a locoregional therapy for patients with unresectable hepatocellular carcinoma (HCC). We examined patient and disease characteristics that might affect survival after Y-90 resin, as well as treatment tolerability.

METHODS: Data from patients with unresectable HCC treated with Y-90 resin at a single institution were reviewed retrospectively. Survival was assessed with Kaplan-Meier curves and log-rank tests. Response was evaluated with the response evaluation criteria in solid tumors (RECIST) criteria. Adverse events (AEs) were noted, and laboratory values were graded with CTCAE v3.0.

RESULTS: Data from 111 patients were analyzed. AEs occurred in 23 patients at 1 week after treatment and in 46 at 3 months. At 6 months, 13 patients had a complete response and 13 had a partial response. Factors associated with longer overall survival (OS) included early-stage disease [27.8 months for patients with Barcelona-Clinic Liver Cancer (BCLC) A

CONCLUSIONS: Several characteristics may prove useful for selecting patients likely to respond well to Y-90 resin. These results should be confirmed in prospective studies.

Keywords: Yttrium-90 resin (Y-90 resin); liver cancer; locoregional therapy; predictive factors; radioembolization

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

  1. Front Oncol. 2014 Jul 29;4:198 - PubMed
  2. Hepatology. 2011 Sep 2;54(3):868-78 - PubMed
  3. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  4. Liver Int. 2015 Jun;35(6):1715-21 - PubMed
  5. Mol Oncol. 2015 Oct;9(8):1501-9 - PubMed
  6. Clin Liver Dis. 2011 May;15(2):223-43, vii-x - PubMed
  7. Clin Gastroenterol Hepatol. 2013 Jun;11(6):604-11; quiz e43-4 - PubMed
  8. Nat Rev Clin Oncol. 2014 Sep;11(9):525-35 - PubMed
  9. Surg Oncol Clin N Am. 2015 Jan;24(1):1-17 - PubMed
  10. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  11. J Natl Compr Canc Netw. 2009 Apr;7(4):350-91 - PubMed
  12. J Hepatol. 2013 Oct;59(4):753-61 - PubMed
  13. J Vasc Interv Radiol. 2014 Jul;25(7):1075-84 - PubMed
  14. Lancet. 2017 Jan 7;389(10064):56-66 - PubMed
  15. Clin Liver Dis. 2015 May;19(2):381-99 - PubMed
  16. World J Radiol. 2012 Sep 28;4(9):405-12 - PubMed
  17. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):13-23 - PubMed
  18. World J Hepatol. 2016 Jun 28;8(18):770-8 - PubMed
  19. Hepatology. 2014 Nov;60(5):1767-75 - PubMed
  20. J Hepatol. 2012 Apr;56(4):908-43 - PubMed
  21. Surg Oncol Clin N Am. 2015 Jan;24(1):167-85 - PubMed

Publication Types